CTLA-4 Control over Foxp3 + Regulatory T Cell Function
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Naturally occurring Foxp3+CD4+ regulatory T cells (Tregs) are essential for maintaining immunological self-tolerance and immune homeostasis. Here, we show that a specific deficiency of cytotoxic T lymphocyte antigen 4 (CTLA-4) in Tregs results in spontaneous development of systemic lymphoproliferation, fatal T cell-mediated autoimmune disease, and hyperproduction of immunoglobulin E in mice, and it also produces potent tumor immunity. Treg-specific CTLA-4 deficiency impairs in vivo and in vitro suppressive function of Tregs-in particular, Treg-mediated down-regulation of CD80 and CD86 expression on dendritic cells. Thus, natural Tregs may critically require CTLA-4 to suppress immune responses by affecting the potency of antigen-presenting cells to activate other T cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The central role that CTLA-4 plays in immunological tolerance is exemplified by experiments in mice that lack the CTLA-4 gene globally or specifically in the Forkhead box P3 (FoxP3)+ Treg compartment. These animals develop lymphoproliferative disorders and die at a young age (25, 26).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Indeed, this process is an important mechanism by which Tregs mediate immune suppression on bystander cells (25).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Of note, although CTLA4 blockade was shown to cause selective depletion of intratumoral Tregs through antibody-dependent cell-mediated cytotoxicity (ADCC) in murine models and ex vivo experiments on human tumor samples (24)(25)(26),”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [24]
In the citing paper
“The CTLA-4 regulatory effects mainly temper the activation of CD4+ helper T cells while boosting regulatory T cells (Tregs) (Doyle et al., 2001; Wing et al., 2008), leading to a pro-tumor immunosuppressive phenotype.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Wing et al., 2008
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Self-citationRegulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Self-citationRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Salomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,081
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Research works printed but not linked: 1
- 10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x · doi:10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x
Cited by
Items 101–200 of 1,010
Mechanisms maintaining peripheral tolerance
Mueller, D. L. (2010) · Nature Immunology · doi:10.1038/ni.1817 · Cited by 461
“Although a portion of the counter-regulatory actions of CTLA-4 relates to its role in mediating the suppressive effects of Foxp3 + CD4 + regulatory T cell”
BackgroundInterpreting type 1 diabetes risk with genetics and single-cell epigenomics
Chiou, J., Geusz, R. J., Okino, M.-L., Han, J. Y., Miller, M., Melton, R., Beebe, E., Benaglio, P., Huang, S., Korgaonkar, K., et al. (2021) · Nature · doi:10.1038/s41586-021-03552-w · Cited by 458
Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
Liu, Y., Dong, Y., Kong, L., Shi, F., Zhu, H., & Yu, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0647-8 · Cited by 447
Principles of regulatory T cell function
Dikiy, S., & Rudensky, A. Y. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.004 · Cited by 445
Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects
Schwab, C., Gabrysch, A., Olbrich, P., Patiño, V., Warnatz, K., Wolff, D., Hoshino, A., Kobayashi, M., Imai, K., Takagi, M., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.055 · Cited by 438
“CTLA-4 is a negative immune regulator essential for the function of regulatory T (Treg) cells, which are responsible for maintaining self-tolerance and immune homeostasis through suppression of T-cell proliferation and differentiation.(4-9) CTLA-4 competes with the costimulatory receptor CD28 for its ligands CD80 and…”
Sage, P. T., Paterson, A. M., Lovitch, S. B., & Sharpe, A. H. (2014) · Immunity · doi:10.1016/j.immuni.2014.12.005 · Cited by 437
“In vitro studies have demonstrated that CTLA-4 can attenuate B7-1 or B7-2 expression on dendritic cells either by downregulation or transendocytosis (Onishi et al., 2008; Qureshi et al., 2011; Wing et al., 2008).”
BackgroundRegulatory immune cells in transplantation
Wood, K. J., Bushell, A., & Hester, J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3227 · Cited by 431
CD4 + T-cell subsets in inflammatory diseases: beyond the T h 1/T h 2 paradigm
Hirahara, K., & Nakayama, T. (2016) · International Immunology · doi:10.1093/intimm/dxw006 · Cited by 417
Duhen, T., Duhen, R., Lanzavecchia, A., Sallusto, F., & Campbell, D. J. (2012) · Blood · doi:10.1182/blood-2011-11-392324 · Cited by 413
Novel Foxo1-dependent transcriptional programs control Treg cell function
Ouyang, W., Liao, W., Luo, C. T., Yin, N., Huse, M., Kim, M. V., Peng, M., Chan, P., Ma, Q., Mo, Y., et al. (2012) · Nature · doi:10.1038/nature11581 · Cited by 413
Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the Morning
Riley, J. L., June, C. H., & Blazar, B. R. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.006 · Cited by 412
Treg and CTLA-4: Two intertwining pathways to immune tolerance
Walker, L. S. K. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.06.006 · Cited by 411
“The finding that mice lacking CTLA-4 only in Treg live longer than those lacking CTLA-4 systemically [81] also points to a functional role for CTLA-4 in the conventional T cell population.”
BackgroundInfluentialNF‐κB: roles and regulation in different CD 4+ T‐cell subsets
Oh, H., & Ghosh, S. (2013) · Immunological Reviews · doi:10.1111/imr.12033 · Cited by 408
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
Serrels, A., Lund, T., Serrels, B., Byron, A., McPherson, R. C., von Kriegsheim, A., Gómez-Cuadrado, L., Canel, M., Muir, M., Ring, J. E., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.001 · Cited by 407
“A clinical study combining agents targeting cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4), which is thought to influence Treg function (Peggs et al., 2009; Quezada et al., 2006; Simpson et al., 2013; Wing et al., 2008), and PD-1, which blocks signals that inhibit T cell function, has reported impressive respons…”
CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
Grosso, J. F., & Jure‐Kunkel, M. (2013) · Europe PMC (PubMed Central) · Cited by 421
High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population
Wagner, D. L., Amini, L., Wendering, D. J., Burkhardt, L.-M., Akyüz, L., Reinke, P., Volk, H.-D., & Schmueck-Henneresse, M. (2019) · Nature Medicine · doi:10.1038/s41591-018-0204-6 · Cited by 399
Ohta, A., Kini, R., Ohta, A., Subramanian, M., Madasu, M., & Sitkovsky, M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00190 · Cited by 398
Immune checkpoint therapy in liver cancer
Xu, F., Jin, T., Zhu, Y., & Dai, C. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0777-4 · Cited by 397
Role of Treg in immune regulation of allergic diseases
Palomares, O., Yaman, G., Azkur, A. K., Akkoc, T., Akdis, M., & Akdis, C. A. (2010) · European Journal of Immunology · doi:10.1002/eji.200940045 · Cited by 394
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
Thomas, R., Al-Khadairi, G., Roelands, J., Hendrickx, W., Dermime, S., Bedognetti, D., & Decock, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00947 · Cited by 393
“In addition, CTLA-4 is constitutively expressed on regulatory T cells, which through competitive binding with B7 and/or induction of B7 internalization reduces the availability of B7 on antigenpresenting cells to form the CD28:B7 costimulatory signal for T cell activation and survival (123, 124).”
BackgroundCTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
Zappasodi, R., Serganova, I., Cohen, I. J., Maeda, M., Shindo, M., Senbabaoglu, Y., Watson, M. J., Leftin, A., Maniyar, R., Verma, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03326-4 · Cited by 393
Bour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391
“However, CTLA-4 cKO mice developed the disease with slower kinetics than CTLA4KO mice, demonstrating once again an effector T-cell-intrinsic role of CTLA-4 in maintaining T-cell homeostasis and tolerance (238).”
BackgroundInfluentialWing, J. B., Ise, W., Kurosaki, T., & Sakaguchi, S. (2014) · Immunity · doi:10.1016/j.immuni.2014.12.006 · Cited by 388
Self-citationHuang, R.-Y., Francois, A., McGray, A. R., Miliotto, A., & Odunsi, K. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1249561 · Cited by 388
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64859 · Cited by 386
Zhao, Y., Lee, C. K., Lin, C.-H., Gassen, R. B., Xu, X., Huang, Z., Xiao, C., Bonorino, C., Lu, L.-F., Bui, J. D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.11.003 · Cited by 383
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Sharma, A., Subudhi, S. K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0762 · Cited by 382
“A murine anti-CTLA-4 mAb containing an IgG2a (clone 9D9) constant region was shown to exhibit enhanced ADCC-dependent intratumoral Treg depletion when compared with IgG2b and IgG1 murine anti-CTLA-4 mAbs (7).”
BackgroundInfluentialLessons learned from the blockade of immune checkpoints in cancer immunotherapy
Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 381
“Beyond its role in dampening activation of Teff cells, CTLA-4 plays a major role in driving the suppressive function of Treg cells [13, 14].”
BackgroundGuidance of regulatory T cell development by Satb1-dependent super-enhancer establishment
Kitagawa, Y., Ohkura, N., Kidani, Y., Vandenbon, A., Hirota, K., Kawakami, R., Yasuda, K., Motooka, D., Nakamura, S., Kondo, M., et al. (2017) · Nature Immunology · doi:10.1038/ni.3646 · Cited by 379
Self-citationRegulatory T cells in allergic diseases
Noval Rivas, M., & Chatila, T. A. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.06.003 · Cited by 373
SHP‐1 and SHP‐2 in T cells: two phosphatases functioning at many levels
Lorenz, U. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00760.x · Cited by 372
“groups developed Foxp3-specific Cre lines (226, 227), which”
BackgroundJang, J.-E., Hajdu, C. H., Liot, C., Miller, G., Dustin, M. L., & Bar-Sagi, D. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.062 · Cited by 372
“…and memory Treg cell populations (Darrasse-Jèze et al., 2009); cyto- toxic T-lymphocyte-associated protein 4 (CTLA-4), a Treg cell effector molecule (Wing et al., 2008); and programmed death 1 (PD-1), a negative costimulatory molecule (Keir et al., 2008), compared to tumor-draining pancreatic…”
BackgroundAt the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 371
Confusing signals: Recent progress in CTLA-4 biology
Walker, L. S. K., & Sansom, D. M. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.12.001 · Cited by 361
Sharpe, A. H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00784.x · Cited by 357
“Recent studies in ICOS) ⁄ ) mice indicate that ICOS can regulate interleukin-21 (IL-21) production, which in turn regulates the expansion of T-helper (Th) type 17 (Th17) cells and TFH. ICOS also plays an important role in controlling IL-10-producing Tregs and peripheral T-cell tolerance.”
BackgroundInfluentialImmunosuppression associated with chronic inflammation in the tumor microenvironment
Wang, D., & DuBois, R. N. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv123 · Cited by 355
“Since Tregs constitutively express CTLA-4 (58,59), loss of CTLA-4 in Tregs led to fatal systemic autoimmune disease (60).”
BackgroundRegulation of the Germinal Center Response
Stebegg, M., Kumar, S. D., Silva-Cayetano, A., Fonseca, V. R., Linterman, M. A., & Graca, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02469 · Cited by 349
FOXO transcription factors throughout T cell biology
Hedrick, S. M., Michelini, R. H., Doedens, A. L., Goldrath, A. W., & Stone, E. L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3278 · Cited by 347
Regulatory T cells and immune regulation of allergic diseases: roles of IL-10 and TGF-β
Palomares, O., Martín-Fontecha, M., Lauener, R., Traidl-Hoffmann, C., Cavkaytar, O., Akdis, M., & Akdis, C. A. (2014) · Genes & Immunity · doi:10.1038/gene.2014.45 · Cited by 347
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin, D. S., & Ribas, A. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.006 · Cited by 346
The development and function of regulatory T cells
Workman, C. J., Szymczak-Workman, A. L., Collison, L. W., Pillai, M. R., & Vignali, D. A. A. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0026-2 · Cited by 344
“This Treg-mediated CTLA-4/APC interaction was important in suppressing the antitumor response, as a robust antitumor response was mounted in the presence of CTLA-4-deficient Tregs compared to wild-type Tregs [196].”
Rotte, A., Jin, J. Y., & Lemaire, V. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx686 · Cited by 344
“CTLA-4 : B7-ligand interaction in mice was shown to cause sequestration of B7-ligands, transendocytosis and degradation of endocytosed ligands resulting in tolerogenic APCs due to significant depletion of the B7 ligands from the surface [81].”
BackgroundHuman FoxP3+ regulatory T cells in systemic autoimmune diseases
Miyara, M., Gorochov, G., Ehrenstein, M., Musset, L., Sakaguchi, S., & Amoura, Z. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.05.004 · Cited by 342
Self-citationHepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation
Bacchetta, R., Barzaghi, F., & Roncarolo, M. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13011 · Cited by 338
Eos Mediates Foxp3-Dependent Gene Silencing in CD4 + Regulatory T Cells
Pan, F., Yu, H., Dang, E. V., Barbi, J., Pan, X., Grosso, J. F., Jinasena, D., Sharma, S. M., McCadden, E. M., Getnet, D., et al. (2009) · Science · doi:10.1126/science.1176077 · Cited by 334
Sage, P. T., & Sharpe, A. H. (2016) · Immunological Reviews · doi:10.1111/imr.12411 · Cited by 330
“results in fatal autoimmunity 6–10 weeks after birth, demonstrating the vital regulatory role of CTLA-4 on Treg subsets (38).”
BackgroundMechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells
Palomares, O., Akdis, M., Martín‐Fontecha, M., & Akdis, C. A. (2017) · Immunological Reviews · doi:10.1111/imr.12555 · Cited by 330
Principles and therapeutic applications of adaptive immunity
Chi, H., Pepper, M., & Thomas, P. G. (2024) · Cell · doi:10.1016/j.cell.2024.03.037 · Cited by 330
Franks, A. L., & Slansky, J. E. (2012) · PubMed · Cited by 326
Ravi, R., Noonan, K. A., Pham, V., Bedi, R., Zhavoronkov, A., Ozerov, I. V., Makarev, E., V. Artemov, A., Wysocki, P. T., Mehra, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02696-6 · Cited by 325
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
Okazaki, T., Okazaki, I.-M., Wang, J., Sugiura, D., Nakaki, F., Yoshida, T., Kato, Y., Fagarasan, S., Muramatsu, M., Eto, T., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100466 · Cited by 324
“The polyclonal activation of T cells in Ctla4/ mice is most likely a result of the dysfunction of T reg cells because immunodeficient mice reconstituted with the mixed BM cells from wild-type and Ctla4/ mice failed to develop the fatal disease of the Ctla4/ mice and the deletion of the CTLA-4 gene in FoxP3+ T re…”
Depletion of fat-resident Treg cells prevents age-associated insulin resistance
Bapat, S. P., Myoung Suh, J., Fang, S., Liu, S., Zhang, Y., Cheng, A., Zhou, C., Liang, Y., LeBlanc, M., Liddle, C., et al. (2015) · Nature · doi:10.1038/nature16151 · Cited by 324
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Granier, C., De Guillebon, E., Blanc, C., Roussel, H., Badoual, C., Colin, E., Saldmann, A., Gey, A., Oudard, S., & Tartour, E. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000213 · Cited by 324
HTLV-1 bZIP Factor Induces T-Cell Lymphoma and Systemic Inflammation In Vivo
Satou, Y., Yasunaga, J.-I., Zhao, T., Yoshida, M., Miyazato, P., Takai, K., Shimizu, K., Ohshima, K., Green, P. L., Ohkura, N., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1001274 · Cited by 319
“This finding may account for the impaired function of Treg cells since these molecules, in particular CTLA-4, play a critical role in Treg-mediated suppression [39].”
BackgroundSelf-citationImmune homeostasis enforced by co-localized effector and regulatory T cells
Liu, Z., Gerner, M. Y., Van Panhuys, N., Levine, A. G., Rudensky, A. Y., & Germain, R. N. (2015) · Nature · doi:10.1038/nature16169 · Cited by 317
Sharma, A., Subudhi, S. K., Blando, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0402 · Cited by 312
T follicular regulatory cells in the regulation of B cell responses
Sage, P. T., & Sharpe, A. H. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.05.005 · Cited by 310
“Treg-specific deletion (using a FoxP3-driven Cre strain) of molecules important in Treg effector function, such as IRF4 or CTLA-4, also results in heightened levels of serum IgG and IgE antibodies [17, 18].”
BackgroundShafiani, S., Tucker-Heard, G., Kariyone, A., Takatsu, K., & Urdahl, K. B. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091885 · Cited by 308
“These effects depend not only on CTLA-4 and LFA-1 but also on TCR-mediated signals (Onishi et al., 2008; Wing et al., 2008).”
BackgroundDepleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci73340 · Cited by 307
“Indeed, the original experiments of Medawar showed that the brain is an immunologically privileged site for skin allografts (45, Indeed, others have shown that OX40, CTLA-4, and CpG could all alter the suppressive properties and, in some cases, the phenotype of Tregs (8, 27, 36–44).”
Weber, J. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.005 · Cited by 306
Delivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
Sobhani, N., Tardiel-Cyril, D. R., Davtyan, A., Generali, D., Roudi, R., & Li, Y. (2021) · Cancers · doi:10.3390/cancers13061440 · Cited by 303
“These structures reveal that ipilimumab and tremelimumab directly compete with CD80 and CD86 at their binding surface, sterically displacing and preventing their interactions with CTLA-4.”
BackgroundInfluentialGenetics of Type 1 Diabetes: What's Next?
Pociot, F., Akolkar, B., Concannon, P., Erlich, H. A., Julier, C., Morahan, G., Nierras, C. R., Todd, J. A., Rich, S. S., & Nerup, J. (2010) · Diabetes · doi:10.2337/db10-0076 · Cited by 300
“CTLA4 genetic variation has a strong effect, presumably via its role in regulation of peripheral tolerance (32), in which the disease-associated CTLA4 haplotype is predisposing to a failure in tolerance to multiple organs or tissues.”
BackgroundBlood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy
Galstyan, A., Markman, J. L., Shatalova, E. S., Chiechi, A., Korman, A. J., Patil, R., Klymyshyn, D., Tourtellotte, W. G., Israel, L. L., Braubach, O., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11719-3 · Cited by 300
Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells
Sasidharan Nair, V., & Elkord, E. (2018) · Immunology & Cell Biology · doi:10.1111/imcb.1003 · Cited by 298
“Moreover, CTLA-4 deficiency affects Treg suppressive function and enhances antitumor immunity.(60) These reports evidently show the critical cell extrinsic function of CTLA-4 expressed by Tregs.”
BackgroundCancer and the Immune System: Basic Concepts and Targets for Intervention
Pardoll, D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.003 · Cited by 298
Regulatory T cells in the treatment of disease
Sharabi, A., Tsokos, M. G., Ding, Y., Malek, T. R., Klatzmann, D., & Tsokos, G. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.148 · Cited by 297
CTLA-4: From mechanism to autoimmune therapy
Hosseini, A., Gharibi, T., Marofi, F., Babaloo, Z., & Baradaran, B. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106221 · Cited by 297
Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy
Bos, P. D., Plitas, G., Rudra, D., Lee, S. Y., & Rudensky, A. Y. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130762 · Cited by 296
“CTLA4 is expressed by T reg cells and is required for their function (Wing et al., 2008).”
BackgroundAlopecia areata: a review of disease pathogenesis
Rajabi, F., Drake, L. A., Senna, M. M., & Rezaei, N. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16808 · Cited by 296
AP-1 Transcription Factors as Regulators of Immune Responses in Cancer
Atsaves, V., Leventaki, V., Rassidakis, G. Z., & Claret, F. X. (2019) · Cancers · doi:10.3390/cancers11071037 · Cited by 293
“Apart from controlling the activation status of CD8+effector cells, there is evidence suggesting that CTLA-4 is necessary for the optimal function of Tregs [98] since CTLA-4 is constitutively expressed in Tregs [99].”
BackgroundA snapshot of the PD-1/PD-L1 pathway
Ghosh, C., Luong, G., & Sun, Y. (2021) · Journal of Cancer · doi:10.7150/jca.57334 · Cited by 292
“Mice with Treg selective ablation of CTLA-4 reiterate the majority of autoimmune phenotypes found in conventional KO mice, including tissue-infiltrating T-cells, harming normal tissues and organs [114].”
BackgroundSpranger, S. (2016) · International Immunology · doi:10.1093/intimm/dxw014 · Cited by 290
Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies
Cervantes-Villagrana, R. D., Albores-García, D., Cervantes-Villagrana, A. R., & García-Acevez, S. J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0205-z · Cited by 290
“T regulatory cells need CTLA-4 for suppressive function, in fact, CTLA-4-deficient Tregs increases immunity against tumors in mice.(100) Similarly, anti-PD-1 monoclonal antibodies interfere with the ability of these cells to communicate with antigen-presenting cells.”
BackgroundProtein Kinase C-θ Mediates Negative Feedback on Regulatory T Cell Function
Zanin-Zhorov, A., Ding, Y., Kumari, S., Attur, M., Hippen, K. L., Brown, M., Blazar, B. R., Abramson, S. B., Lafaille, J. J., & Dustin, M. L. (2010) · Science · doi:10.1126/science.1186068 · Cited by 289
Costimulatory and coinhibitory receptors in anti‐tumor immunity
Driessens, G., Kline, J., & Gajewski, T. F. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00771.x · Cited by 286
“deletion of CTLA-4 in Tregs (CKO mice) (139).”
BackgroundJie, H.-B., Gildener-Leapman, N., Li, J., Srivastava, R. M., Gibson, S. P., Whiteside, T. L., & Ferris, R. L. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.645 · Cited by 286
“For example, the FOXP3þ Treg-specific loss of CTLA-4 is sufficient to induce fatal lymphoproliferative disease, which is similar to that observed in CTLA-4-deficient mice (Wing et al, 2008).”
ResultTomura, M., Honda, T., Tanizaki, H., Otsuka, A., Egawa, G., Tokura, Y., Waldmann, H., Hori, S., Cyster, J. G., Watanabe, T., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40926 · Cited by 282
Regulatory T Cells: Differentiation and Function
Plitas, G., & Rudensky, A. Y. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0193 · Cited by 282
“molecules CD80 and CD86 expression on DCs (4, 28).”
BackgroundInfluentialResponse to self antigen imprints regulatory memory in tissues
Rosenblum, M. D., Gratz, I. K., Paw, J. S., Lee, K., Marshak-Rothstein, A., & Abbas, A. K. (2011) · Nature · doi:10.1038/nature10664 · Cited by 281
Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.04.002 · Cited by 280
“On the one hand, mice selectively lacking CTLA-4 on Treg cells (Foxp3-IRES-Cre Ctla4f/f mice) develop multi-organ autoimmunity similar to that of complete CTLA-4 knockout mice [21], indicating that CTLA-4 can promote Treg suppressive functions.”
BackgroundShifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
Quezada, S. A., Peggs, K. S., Simpson, T. R., & Allison, J. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01007.x · Cited by 276
“Finally, in addition to its role in controlling Teff function, CTLA-4 has an important role in Treg-mediated suppression (95), as further evidenced by the recent demonstration that Treg-specific CTLA-4 deficiency in conditional knockout mice is associated with a profound reduction in their suppressive capacity (96).”
BackgroundThe immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy
Buchan, S. L., Rogel, A., & Al-Shamkhani, A. (2018) · Blood · doi:10.1182/blood-2017-07-741025 · Cited by 276
Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis
Kishore, M., Cheung, K. C. P., Fu, H., Bonacina, F., Wang, G., Coe, D., Ward, E. J., Colamatteo, A., Jangani, M., Baragetti, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.10.017 · Cited by 276
“CTLA-4-deficient mice display normal numbers of Treg lymphocytes, which however appear to be defective in their suppressive function in vivo (Wing et al., 2008) but not in vitro (Tang et al.”
BackgroundTherapeutic cancer vaccines: Are we there yet?
Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271
“Further, CTLA-4 is constitutively expressed on the surface of Tregs, where it contributes to the ability of these cells to antagonize the effector functions of responding T cells (104), including anti-tumor T cells (105).”
BackgroundRapp, M., Wintergerst, M. W. M., Kunz, W. G., Vetter, V. K., Knott, M. M. L., Lisowski, D., Haubner, S., Moder, S., Thaler, R., Eiber, S., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20170277 · Cited by 271
“T reg contacts are critically important for immune regulation by T regs (Tang et al., 2006; Onishi et al., 2008;Wing et al., 2008; Sakaguchi et al., 2009).”
BackgroundFunction of a Foxp3 cis -Element in Protecting Regulatory T Cell Identity
Li, X., Liang, Y., LeBlanc, M., Benner, C., & Zheng, Y. (2014) · Cell · doi:10.1016/j.cell.2014.07.030 · Cited by 270
Initiation and regulation of T-cell responses in tuberculosis
Urdahl, K. B., Shafiani, S., & Ernst, J. D. (2011) · Mucosal Immunology · doi:10.1038/mi.2011.10 · Cited by 268
Jie, H.-B., Schuler, P. J., Lee, S. C., Srivastava, R. M., Argiris, A., Ferrone, S., Whiteside, T. L., & Ferris, R. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2788 · Cited by 266
“For example, Foxp3 Treg-specific loss of CTLA-4 is sufficient to induce fatal lymphoproliferative disease, which is reminiscent of findings observed in CTLA-4-deficient mice (35).”
The Pivotal Role of Regulatory T Cells in the Regulation of Innate Immune Cells
Okeke, E. B., & Uzonna, J. E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00680 · Cited by 264
“This implies that decrease in number of Tregs relative to APCs will limit trogocytosis of CD80 and CD86 by CTLA-4+ Tregs leading to higher CD28 costimulation and more aggressive T cell response (180).”
ResultInfluentialAkkaya, B., Oya, Y., Akkaya, M., Al Souz, J., Holstein, A. H., Kamenyeva, O., Kabat, J., Matsumura, R., Dorward, D. W., Glass, D. D., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0280-2 · Cited by 263
Emerging Functions of Regulatory T Cells in Tissue Homeostasis
Sharma, A., & Rudra, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00883 · Cited by 262
“In case of skin wound-induced inflammation, Tregs acquire a highly activated phenotype with higher surface expression of CTLA4 and ICOS.”
BackgroundInfluentialRay, A., Basu, S., Williams, C. B., Salzman, N. H., & Dittel, B. N. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103354 · Cited by 261
PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
Tan, C. L., Kuchroo, J. R., Sage, P. T., Liang, D., Francisco, L. M., Buck, J., Thaker, Y. R., Zhang, Q., McArdel, S. L., Juneja, V. R., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20182232 · Cited by 258
Kumagai, S., Togashi, Y., Sakai, C., Kawazoe, A., Kawazu, M., Ueno, T., Sato, E., Kuwata, T., Kinoshita, T., Yamamoto, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.016 · Cited by 257
Jain, N., Nguyen, H., Chambers, C., & Kang, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910341107 · Cited by 256
“Further, Ctla4 deletion specifically in Treg cells by FOXP3-Cre precipitates autoimmunity akin to Ctla4 mice, although the life span of these mice is significantly extended compared toCtla4mice (11).”
BackgroundResultInfluentialBasis of CTLA-4 function in regulatory and conventional CD4+ T cells
Tai, X., Van Laethem, F., Pobezinsky, L., Guinter, T., Sharrow, S. O., Adams, A., Granger, L., Kruhlak, M., Lindsten, T., Thompson, C. B., et al. (2012) · Blood · doi:10.1182/blood-2011-11-388918 · Cited by 251
Leung, S., Liu, X., Fang, L., Chen, X., Guo, T., & Zhang, J. (2010) · Cellular & Molecular Immunology · doi:10.1038/cmi.2010.22 · Cited by 251
“97 Furthermore, Treg cells could downregulate or inhibit upregulation of CD80/86 in APCs through CTLA-4”
Fulton, R. B., Meyerholz, D. K., & Varga, S. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000423 · Cited by 251
Metadata
- Authors
- Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S.
- Affiliations
- Tohoku University (JP)
- Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
- Corresponding author
- Wing, Kajsa
- Sakaguchi, Shimon
- Venue
- Science
- Published
- 2008-10-10
- Volume
- 322
- Issue
- 5899
- Pages
- 271-275
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2061071534
- Cited by
- 2,956
- References
- 25
- Citations by year
- 2026: 122 · 2025: 129 · 2024: 154 · 2023: 142 · 2022: 162 · 2021: 198 · 2020: 186 · 2019: 205 · 2018: 197 · 2017: 187 · 2016: 174 · 2015: 162 · 2014: 158 · 2013: 170 · 2012: 167
- FWCI
- 61.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4, Foxp3+ regulatory T cells, Treg suppressive function, lymphoproliferation, autoimmune disease, immunoglobulin E, antitumor immunity, dendritic cells, CD80, CD86, antigen presentation, immune tolerance
- MeSH terms
- Animals, Antigen-Presenting Cells, Autoimmune Diseases, Dendritic Cells, Female, Immunoglobulin E, Immunoglobulin G, Immune Tolerance, Leukemia, Lymphocyte Activation, Lymphocytes, Male, Mice, Inbred BALB C, Down-Regulation, Autoimmunity, Antigens, CD, B7-1 Antigen, CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, B7-2 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.